• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

运动波动的预防与治疗。

Prevention and treatment of motor fluctuations.

作者信息

Stocchi Fabrizio

机构信息

IRCCS NEUROMED Pozzilli (15), Institute of Neuroscience, Viale dell'Università 30, 00185 Rome, Italy.

出版信息

Parkinsonism Relat Disord. 2003 Aug;9 Suppl 2:S73-81. doi: 10.1016/s1353-8020(03)00021-x.

DOI:10.1016/s1353-8020(03)00021-x
PMID:12915071
Abstract

The symptoms of Parkinson's disease can become increasingly difficult to control as the disease advances, particularly with the development of motor complications, such as end-of-dose wearing-off and dyskinesias, following long-term therapy. At this stage, the patient is frequently referred to a Parkinson's disease specialist for advice on the management of their disease. In this review we provide an overview of the Parkinson's disease specialist's strategies for coping with such problems. This includes strategy to prevent or delay motor fluctuations and the concept of the long duration response. The paper also includes establishing the optimum and most rational levodopa treatment schedule, improving levodopa absorption, use of COMT-inhibition, the addition of oral dopaminergic agonists, and the use of subcutaneous injections or infusions of apomorphine or lisuride. Finally, we highlight the increasing importance of treatment strategies that stimulate dopamine receptors in a more continuous, less pulsatile manner as a way of reducing the risk of developing treatment-associated motor complications.

摘要

随着帕金森病的进展,其症状会越来越难以控制,尤其是在长期治疗后出现运动并发症,如剂末疗效减退和异动症时。在这个阶段,患者经常会被转介给帕金森病专家,以获取有关疾病管理的建议。在这篇综述中,我们概述了帕金森病专家应对此类问题的策略。这包括预防或延迟运动波动的策略以及长期反应的概念。本文还包括制定最佳且最合理的左旋多巴治疗方案、改善左旋多巴吸收、使用儿茶酚-O-甲基转移酶(COMT)抑制剂、添加口服多巴胺能激动剂以及使用阿扑吗啡或利苏瑞肽的皮下注射或输注。最后,我们强调以更持续、更少脉冲式的方式刺激多巴胺受体的治疗策略对于降低发生与治疗相关的运动并发症风险的重要性日益增加。

相似文献

1
Prevention and treatment of motor fluctuations.运动波动的预防与治疗。
Parkinsonism Relat Disord. 2003 Aug;9 Suppl 2:S73-81. doi: 10.1016/s1353-8020(03)00021-x.
2
Managing the critical problems of advanced Parkinson's disease.管理晚期帕金森病的危急问题。
Expert Rev Neurother. 2002 Nov;2(6):835-47. doi: 10.1586/14737175.2.6.835.
3
Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.治疗晚期帕金森病伴有严重症状波动和异动症患者的策略。
Clin Neuropharmacol. 1997 Apr;20(2):95-115. doi: 10.1097/00002826-199704000-00001.
4
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.阿朴吗啡和左旋多巴输注治疗晚期帕金森病的运动波动和运动障碍。
J Neural Transm (Vienna). 2018 Aug;125(8):1131-1135. doi: 10.1007/s00702-018-1906-0. Epub 2018 Jul 13.
5
Extending levodopa action: COMT inhibition.延长左旋多巴作用时间:儿茶酚-O-甲基转移酶抑制
Neurology. 1998 Jun;50(6 Suppl 6):S27-32; discussion S44-8. doi: 10.1212/wnl.50.6_suppl_6.s27.
6
Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.皮下注射阿扑吗啡:关于其在帕金森病中应用的循证综述
Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001.
7
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.托卡朋:作为帕金森病辅助治疗药物的药理学和临床应用评价。
Clin Interv Aging. 2009;4:109-13. doi: 10.2147/cia.s3787. Epub 2009 May 14.
8
Medical management of levodopa-associated motor complications in patients with Parkinson's disease.帕金森病患者左旋多巴相关运动并发症的药物治疗
CNS Drugs. 2007;21(8):677-92. doi: 10.2165/00023210-200721080-00005.
9
Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.帕金森病患者中,利苏瑞得静脉输注与口服左旋多巴的前瞻性随机试验。
Brain. 2002 Sep;125(Pt 9):2058-66. doi: 10.1093/brain/awf214.
10
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.托卡朋抑制儿茶酚-O-甲基转移酶可减少帕金森病症状波动患者的“剂末现象”及左旋多巴需求量。
Neurology. 1998 May;50(5 Suppl 5):S46-53. doi: 10.1212/wnl.50.5_suppl_5.s46.

引用本文的文献

1
Advanced Parkinson's disease treatment patterns in Italy: an observational study interim analysis.意大利的先进帕金森病治疗模式:一项观察性研究中期分析。
Ann Med. 2024 Dec;56(1):2315226. doi: 10.1080/07853890.2024.2315226. Epub 2024 Feb 21.
2
Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.线粒体功能障碍导致的进行性帕金森病:来自 MitoPark 小鼠模型的启示。
Exp Neurol. 2021 Jul;341:113707. doi: 10.1016/j.expneurol.2021.113707. Epub 2021 Mar 20.
3
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
罗替高汀透皮贴剂治疗运动和非运动症状帕金森病:12 年临床经验回顾。
CNS Drugs. 2021 Feb;35(2):215-231. doi: 10.1007/s40263-020-00788-4. Epub 2021 Feb 9.
4
L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study.帕金森病中泡腾美多芭/卡比多巴与标准释放左旋多巴/卡比多巴片的左旋多巴药代动力学特征:一项随机研究。
Parkinsons Dis. 2015;2015:369465. doi: 10.1155/2015/369465. Epub 2015 Jun 10.
5
Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?WOQ-9 是否有助于识别帕金森病的非运动症状波动?
J Neural Transm (Vienna). 2012 Mar;119(3):373-80. doi: 10.1007/s00702-011-0683-9. Epub 2011 Jul 17.
6
Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR.由固态核磁共振引导设计的α-突触核蛋白聚集的N-甲基化肽抑制剂
J Am Chem Soc. 2008 Jun 25;130(25):7873-81. doi: 10.1021/ja075356q. Epub 2008 May 30.
7
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.间歇性皮下注射阿扑吗啡治疗帕金森病“关”期发作:一项为期6个月的开放标签研究。
CNS Drugs. 2008;22(6):519-27. doi: 10.2165/00023210-200822060-00005.